The size of the prostate cancer market in the Asia Pacific is estimated to value USD 19.01 billion by 2026 from USD 11.46 billion in 2021, growing at a CAGR of 10.65% during the forecast period.
Prostate cancer is a common term used for the diseased situations in which abnormal cells grow and infect uncontrollably in the prostate. New product inventions, partnership agreements, collaborations, and acquisitions are some of the key strategies adopted by the players to get a significant market share in the forecast period.
Advancement in technology, personalized medicine, cost-effective treatment procedures are a few other factors expected to boost the Asia-Pacific prostate cancer market. RIn addition, the rising incidence of prostate cancers and the availability of various treatment modalities are also fuelling the market growth.
However, limited commercially available drugs and treatments for this cancer are the challenges restraining the growth of the prostate cancer market. Nevertheless, The Asia Pacific market is estimated to show a substantial growth rate deeds in promising countries.
This research report on the APAC prostate cancer market has been segmented and sub-segmented into the following categories.
By Diagnostic Techniques:
By Surgery:
By Radiation Therapy:
By Chemotherapy:
By Country:
Asia-Pacific offers attractive potential for key players in the prostate cancer market due to increased awareness of prostate cancer treatment and acceptance of prostate cancer treatment products. In addition, improvements in healthcare infrastructure, an increase in the number of hospitals with modern medical facilities, a growing R&D sector, a rise in healthcare reforms, and technical advancements in the field of healthcare all contribute to market expansion. Over the forecast period, the market for castrate-resistant prostate cancer in the Asia Pacific is expected to grow rapidly. This is the case because of the existence of significant oncology firms and expanding R&D investments in nations like China and Japan. On the other hand, it has increased the development of prostate cancer drugs. Other factors driving the growth of the Asia-Pacific prostate cancer treatment market include leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capitalize on high growth opportunities in the market, a large population base, and high disposable incomes.
Because China has a large population, the total number of tests is projected to be larger than in other regions. Therefore, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. Prostate cancer is, nonetheless, extremely common in Australia. The most significant rates of prostate cancer have been observed in Australia and New Zealand, owing to the widespread use of prostate-specific antigen (PSA) screening in these countries. However, prostate cancer incidence has been observed to differ from country to country in the Asia Pacific. Because Japan has a large geriatric population, the country is expected to gain a significant market share during the forecast period. To stay competitive, market companies are using various growth methods such as new product launches, mergers and acquisitions, government partnerships, and technological advancements to contribute significantly to market growth.
KEY MARKET PLAYERS:
Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech are a few of the promising companies in the APAC prostate cancer market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Techniques
5.1.1 Introduction
5.1.2 Digital Rectal Exam (DRE)
5.1.3 Prostate Specific Antigen Test (PSA)
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Surgery
5.2.1 Introduction
5.2.2 Radical Prostatectomy
5.2.3 Orchidectomy
5.2.4 Trans Urethral Resection (TUR)
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Radiation Therapy
5.3.1 Introduction
5.3.2 External Beam Radiation Therapy
5.3.2.1 3D Conformal Radiation Therapy
5.3.2.2 Intensity Modulated Radiation Therapy
5.3.2.3 Stereotactic Body Radiation Therapy
5.3.2.4 Proton Beam Radiation Therapy
5.3.3 Brachytherapy
5.3.3.1 Permanent Brachytherapy
5.3.3.2 Temporary Brachytherapy
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 Chemotherapy
5.4.1 Introduction
5.4.2 Docetaxel
5.4.3 Etoposide
5.4.4 Vinblastine
5.4.5 Carboplatin
5.4.6 Vinorelbine
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Techniques
6.1.3.3 By Surgery
6.1.3.4 By Radiation Therapy
6.1.3.5 By Chemotherapy
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Techniques
6.1.4.3 By Surgery
6.1.4.4 By Radiation Therapy
6.1.4.5 By Chemotherapy
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Techniques
6.1.5.3 By Surgery
6.1.5.4 By Radiation Therapy
6.1.5.5 By Chemotherapy
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sanofi S.A
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 AstraZeneca
8.4 AbbVie
8.5 Varian Medical Systems
8.6 Elekta
8.7 Theragenics
8.8 Pfizer
8.9 Novartis
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
